Pharmaceuticals

June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death and need for procedures to restore the blood flow to the heart in patie...

Patients with hypertension after renal artery stenting who do not respond to drug treatment may have another option. 

April 10, 2014 — The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations for an increased use of radio frequency (RF) ablation in the treatment of non-valvular atrial fibrillation, the addition of three...

Heparin More Effective Than Bivalirudin in Treating Patients During PCI

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention (PCI) after a heart attack,...

statins, pharmaceuticals, cholesterol
A new study by researchers at Wake Forest Baptist Medical Center suggests that the use of cholesterol-lowering statins may help prolong the lives of...
CVS Caremark Study Copay Heart Attack Non-white Patient Outcomes
A study by researchers at CVS Caremark, Aetna and Brigham and Women’s Hospital published in the May issue of Health Affairs, finds that eliminating copays...
LipoScience Inc. announced the publication of the first large-scale real world study evidencing a link between low LDL-P and reduced cardiovascular disease (...
The U.S. Food and Drug Administration (FDA) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with...
Zontivity (vorapaxar) tablets reduce the risk of heart attack, stroke, cardiovascular death and need for procedures to restore the blood
Atherotech Diagnostics Lab offers warfarin sensitivity, Plavix sensitivity and thrombophilia risk tests. The warfarin and Plavix...
Liptruzet (pronounced LIP-true-zett) contains ezetimibe, an efficacious LDL cholesterol lowering therapy, and atorvastatin, currently one...
The U.S. Food and Drug Administration approved Kcentra (prothrombin complex concentrate, human) for the urgent reversal of vitamin K...

Articles

LipoScience Inc. announced the publication of the first large-scale real world study evidencing a link between low LDL-P and reduced cardiovascular disease (...
Strokes kill nearly 130,000 Americans every year, according to the Centers for Disease Control and Prevention. Because approximately 30 percent of strokes are...
June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke,...
Journal of Endovascular Therapy Hypertension Renal Denervation Therapy
Patients with hypertension after renal artery stenting who do not respond to drug treatment may have another option. 

Video Center

A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost...
2 weeks 1 day ago
There were several new cardiovascular ultrasound technology advances highlighted at the American...
3 weeks 7 hours ago
The key cardiology news coming out of the 2014 meeting for the Society of Nuclear Medicine and...
5 weeks 2 hours ago
CVIS, cardiovascular information system, webinar
Join Ascendian Healthcare Consulting and GE Healthcare during a webinar Wednesday, July 16 to learn about the access, productivity, and revenue cycle efficiency benefits of a modern cardiovascular...
The webinar "Implementing Robotic PCI — Why and How to Start a Successful Program" defines optimal strategies for launching a successful robotic percutaneous coronary intervention (PCI) program. The...
This webinar focuses on implementation of different strategies to help clinicians reduce radiation exposure during interventional cardiology procedures, both for patient and operators. It offers an...

Comparison Charts

Sorry there is no data available